| Dr Brojesh Chandra Pakrashi, MD FACC | |
|
6688 Ridge Road, Suite #1420, Parma, OH 44129 | |
| (440) 887-0646 | |
| (440) 887-0636 |
| Full Name | Dr Brojesh Chandra Pakrashi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 6688 Ridge Road, Parma, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124118898 | NPI | - | NPPES |
| 0384388 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 043413 (Ohio) | Primary |
| Entity Name | Brojesh C Pakrashi M.d. Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124245022 PECOS PAC ID: 1052479516 Enrollment ID: O20081028000256 |
News Archive
The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.
Roll Call: Senate Republicans have stepped-up their message attack against President Barack Obama's latest push to pass health reform. "A key element of the Senate GOP's plan appears to be to try to scare House Democrats against voting for the health care plan, arguing that there's no guarantee that the Senate approves a reconciliation package."
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube.
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects. In addition, the influence of the placebo effect on the efficacy of antidepressants is unclear.
The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brojesh Chandra Pakrashi, MD FACC 6688 Ridge Road, Suite #1420, Parma, OH 44129-5706 Ph: (440) 887-0646 | Dr Brojesh Chandra Pakrashi, MD FACC 6688 Ridge Road, Suite #1420, Parma, OH 44129 Ph: (440) 887-0646 |
News Archive
The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.
Roll Call: Senate Republicans have stepped-up their message attack against President Barack Obama's latest push to pass health reform. "A key element of the Senate GOP's plan appears to be to try to scare House Democrats against voting for the health care plan, arguing that there's no guarantee that the Senate approves a reconciliation package."
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube.
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects. In addition, the influence of the placebo effect on the efficacy of antidepressants is unclear.
The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).
› Verified 2 days ago
Fariha Shad, M.D Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 12301 Snow Rd, Parma, OH 44130 Phone: 216-524-7377 Fax: 216-265-4459 | |
Dr. Charles Harding King, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 5550 Vanture Drive, Cuyahoga County Board Of Health, Parma, OH 44130 Phone: 216-201-2041 | |
Daniela Susoiu Tcaciuc, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6681 Ridge Rd, Suite 400, Parma, OH 44129 Phone: 440-743-2450 Fax: 440-743-2451 | |
Dr. Stephen Joseph Clary, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 6087 Ridge Rd, Suite 2, Parma, OH 44129 Phone: 440-884-7272 Fax: 440-884-7972 | |
Dr. Carol Ann D'souza, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12301 Snow Rd, Parma, OH 44130 Phone: 216-621-5600 Fax: 216-479-5554 | |
Dr. Milton C Wong, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12301 Snow Rd, Parma, OH 44130 Phone: 216-362-2185 | |
Dr. Nuzhat Inayat Ashai, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12301 Snow Rd, Parma, OH 44130 Phone: 216-621-5600 Fax: 216-265-4459 |